company background image
TFFP logo

TFF Pharmaceuticals NasdaqCM:TFFP Stock Report

Last Price

US$2.05

Market Cap

US$6.8m

7D

-6.0%

1Y

-82.2%

Updated

29 May, 2024

Data

Company Financials +

TFF Pharmaceuticals, Inc.

NasdaqCM:TFFP Stock Report

Market Cap: US$6.8m

TFFP Stock Overview

A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.

TFFP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TFF Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TFF Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.05
52 Week HighUS$15.95
52 Week LowUS$1.54
Beta1.44
1 Month Change-24.35%
3 Month Change-66.56%
1 Year Change-82.17%
3 Year Change-99.25%
5 Year Changen/a
Change since IPO-98.38%

Recent News & Updates

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharma: The Potential Is Still Very Much Present

Aug 29

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

Aug 09

TFF Pharmaceuticals expands R&D operations with new Austin facility

Jul 14

TFF Pharmaceuticals: A Highly Attractive Basket Of Options

May 23

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17
We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06
Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Dec 02

Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth

Sep 16
Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth

TFF Pharmaceuticals: Cautiously Optimistic

Sep 09

TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic

Jul 27

Shareholder Returns

TFFPUS PharmaceuticalsUS Market
7D-6.0%-1.7%-0.6%
1Y-82.2%17.9%25.4%

Return vs Industry: TFFP underperformed the US Pharmaceuticals industry which returned 17.9% over the past year.

Return vs Market: TFFP underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is TFFP's price volatile compared to industry and market?
TFFP volatility
TFFP Average Weekly Movement19.1%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement5.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: TFFP's share price has been volatile over the past 3 months.

Volatility Over Time: TFFP's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201819Harlan Weismantffpharma.com

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.

TFF Pharmaceuticals, Inc. Fundamentals Summary

How do TFF Pharmaceuticals's earnings and revenue compare to its market cap?
TFFP fundamental statistics
Market capUS$6.85m
Earnings (TTM)-US$19.93m
Revenue (TTM)US$885.72k

7.2x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TFFP income statement (TTM)
RevenueUS$885.72k
Cost of RevenueUS$11.97m
Gross Profit-US$11.09m
Other ExpensesUS$8.84m
Earnings-US$19.93m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.43
Gross Margin-1,251.71%
Net Profit Margin-2,249.82%
Debt/Equity Ratio0%

How did TFFP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.